Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453628 | 1.00 | AKR1B1 (0.37) | AKR1B1MPILMNAL3MBTL1 | |
| SCHEMBL5770928 | 1.00 | AKR1B1 (0.37) | AKR1B1MPILMNAL3MBTL1 | |
| SCHEMBL5771370 | 1.00 | AKR1B1 (0.37) | AKR1B1MPILMNAL3MBTL1 | |
| SCHEMBL3142523 | 1.00 | AKR1B1 (0.37) | AKR1B1MPILMNAL3MBTL1 | |
| SCHEMBL7149588 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL7155793 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL5414822 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL7151920 | 0.88 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1 | |
| SCHEMBL1367677 | 0.88 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1 | |
| SCHEMBL14409028 | 0.88 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4512890-A2 | GENETICALLY ENGINEERED HERMATOPOIETIC STEM CELLS AND USES THEREOF | Vor Biopharma, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240229109-A1 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | MODERNATX, INC. (US) | 2024-07-11 | — | — | US | claimed |
| CN-118076741-A | Modified mRNA, modified non-coding RNA and uses thereof | 布罗德研究所股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| EP-4337331-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | The Broad Institute Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2023141474-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| US-9186399-B2 | Immune stimulatory oligonucleotide analogs containing modified sugar moieties | AdiutTide Pharmaceuticals GmbH (DE) | 2015-11-17 | — | — | US | claimed |
| EP-2197488-B1 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2014-05-07 | — | — | EP | claimed |
| US-8202850-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-20110229456-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | IDERA PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | claimed |
| WO-2009047610-A1 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES | COLEY PHARMACEUTICAL GMBH (DE) | 2009-04-16 | — | — | WO | claimed |
| US-20080152662-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | IDERA PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | claimed |
| EP-1601789-A4 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | IDERA PHARMACEUTICALS INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-7276489-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| EP-1601789-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | HYBRIDON, INC. (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2004-10-07 | — | — | US | claimed |
| WO-2004064782-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | HYBRIDON, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | HYBRIDON, INC. | 2004-05-20 | — | — | US | claimed |
| EP-1393745-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends | HYBRIDON, INC. (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2003035836-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC. (US) | 2003-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, TLR5 | AKR1B1 2309/4885MPI 116/4885LMNA 4834/4885 |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, ENTPD5 | AKR1B1 2664/4885MPI 93/4885LMNA 4649/4885 |
| US-20080152662-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, TLR9 | AKR1B1 2693/4885MPI 89/4885LMNA 4690/4885 |
| US-20110229456-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | TLR5, TLR3, TLR9 | AKR1B1 2693/4885MPI 89/4885LMNA 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.